Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Reactive arthritis induced by intravesical BCG therapy for bladder cancer
View through CrossRef
Cancers of the bladder could be treated with intravesical instillation of BCG therapy. This treatment could lead to some complications. Osteoarticular ones are relatively uncommon. We describe an original observation, illustrating the development of reactive arthritis after intravesical BCG therapy. A 60-year-old man was followed for a T1G3 transitional papillary carcinoma of the bladder and was treated with intravesical BCG immunotherapy. Within the sixth intravesical instillation, he presented with polyarthritis confirmed by musculoskeletal ultrasound. The erythrocyte sedimentation rate was 100 mm without leukocytosis. The viral and bacterial serologies and immunological tests were negative. The ophthalmological examination revealed left conjunctivitis. Treatment with non-steroidal anti-inflammatory drugs was started, combined with the discontinuation of the intravesical instillation. No recurrence has been reported with a current decline of 2 years.
Title: Reactive arthritis induced by intravesical BCG therapy for bladder cancer
Description:
Cancers of the bladder could be treated with intravesical instillation of BCG therapy.
This treatment could lead to some complications.
Osteoarticular ones are relatively uncommon.
We describe an original observation, illustrating the development of reactive arthritis after intravesical BCG therapy.
A 60-year-old man was followed for a T1G3 transitional papillary carcinoma of the bladder and was treated with intravesical BCG immunotherapy.
Within the sixth intravesical instillation, he presented with polyarthritis confirmed by musculoskeletal ultrasound.
The erythrocyte sedimentation rate was 100 mm without leukocytosis.
The viral and bacterial serologies and immunological tests were negative.
The ophthalmological examination revealed left conjunctivitis.
Treatment with non-steroidal anti-inflammatory drugs was started, combined with the discontinuation of the intravesical instillation.
No recurrence has been reported with a current decline of 2 years.
Related Results
Apoptosis Activity of the Mouse Macrophage Cell Line J774A.1 Infected with a Recombinant BCG consisting the C-Terminus of Merozoite Surface Protein-1 of Plasmodium falciparum
Apoptosis Activity of the Mouse Macrophage Cell Line J774A.1 Infected with a Recombinant BCG consisting the C-Terminus of Merozoite Surface Protein-1 of Plasmodium falciparum
Macrophage apoptosis exerts an efficient mechanism in controlling intracellular infection during innate immune response against various pathogens including malaria parasites. This ...
A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin
A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin
ABSTRACT
Tuberculosis (TB) remains a global health crisis. Following encouraging clinical results of subunit vaccination and revaccination with Bacillus Calmette-Gu...
Data from E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer
Data from E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer
<div>Abstract<p>Bladder cancer is a common malignant disease, with non–muscle-invasive bladder cancer (NMIBC) representing the majority of tumors. This cancer subtype i...
Data from E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer
Data from E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer
<div>Abstract<p>Bladder cancer is a common malignant disease, with non–muscle-invasive bladder cancer (NMIBC) representing the majority of tumors. This cancer subtype i...
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or muscle invasive). Patients with muscle-invasive dis...
TAR-200: Investigational intravesical drug delivery system for bladder cancer
TAR-200: Investigational intravesical drug delivery system for bladder cancer
Bladder cancer is second among the most common urothelial malignancy and one of the most expensive in terms of treatment. Localized bladder cancer is classified into non-muscle inv...
<b>PATTERN AND BURDEN OF COMPLICATIONS OF INTRAVESICAL BACILLUS CALMETTE-GUERIN AFTER TRANSURETHRAL RESECTION OF BLADDER TUMOR IN NON-MUSCLE INVASIVE BLADDER TUMOR</b>
<b>PATTERN AND BURDEN OF COMPLICATIONS OF INTRAVESICAL BACILLUS CALMETTE-GUERIN AFTER TRANSURETHRAL RESECTION OF BLADDER TUMOR IN NON-MUSCLE INVASIVE BLADDER TUMOR</b>
Objective: To determine pattern and burden of complications of Intravesical Bacillus Calmette-Guerin after transurethral resection of bladder tumor in non-muscle invasive bladder t...
Prospective Randomized Study between Intravesical BCG and Mitomycin-C for Non-Muscle-Invasive Urothelial Carcinoma of Urinary-Bladder Post TURBT
Prospective Randomized Study between Intravesical BCG and Mitomycin-C for Non-Muscle-Invasive Urothelial Carcinoma of Urinary-Bladder Post TURBT
Background: Approximately 70% of urinary bladder cancer are non-muscle invasive at presentation. It is notorious for its high incidence and recurrence rate. The five-year recurrenc...